NCT05339672View on ClinicalTrials.gov

Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban

UnknownOBSERVATIONAL
Enrollment

26

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Drug-drug Interaction
Interventions
OTHER

Blood sampling - Pharmacokinetic assessment

Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Canisius Wilhelmina Ziekenhuis, Nijmegen

RECRUITING

Radboudumc, Nijmegen

NOT_YET_RECRUITING

Franciscus Gasthuis en Vlietland hospital, Rotterdam

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT05339672 - Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban | Biotech Hunter | Biotech Hunter